Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Bioventus (BVS) EPS (Weighted Average and Diluted) (2021 - 2025)

Bioventus' EPS (Weighted Average and Diluted) history spans 5 years, with the latest figure at $0.21 for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) changed N/A year-over-year to $0.21; the TTM value through Dec 2025 reached $0.33, up 158.93%, while the annual FY2025 figure was $0.33, 158.93% up from the prior year.
  • EPS (Weighted Average and Diluted) reached $0.21 in Q4 2025 per BVS's latest filing, up from $0.05 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.86 in Q4 2023 to a low of -$1.76 in Q4 2022.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.19, with a median of -$0.08 recorded in 2024.
  • Peak YoY movement for EPS (Weighted Average and Diluted): crashed 94482.76% in 2022, then surged 265.38% in 2023.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.0 in 2021, then plummeted by 94482.76% to -$0.52 in 2022, then soared by 265.38% to $0.86 in 2023, then plummeted by 109.3% to -$0.08 in 2024, then soared by 362.5% to $0.21 in 2025.
  • Per Business Quant, the three most recent readings for BVS's EPS (Weighted Average and Diluted) are $0.21 (Q4 2025), $0.05 (Q3 2025), and $0.11 (Q2 2025).